Positron emission tomography‐computed tomography on predicting the efficacy of targeted therapy for lung adenocarcinoma
Xiaoxiang Rong(Nanfang Hospital), Rongcheng Luo(Hebei Medical University), Jinzhang Chen(Nanfang Hospital), Quanshi Wang(Nanfang Hospital), Changxuan You(Southern Medical University), Rong Li(SAIC-GM (China)), Xiaoli Cai(Wuhan University of Science and Technology), Junyi Zhang(Nanfang Hospital), Wenyun Wu(Nanfang Hospital), Chuanxin Liu(Affiliated Hospital of Jining Medical University)
Cited by 5
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis
|Nature Communications|2017|159